Shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) traded up 4.5% on Monday . The company traded as high as $8.29 and last traded at $7.40. 277,078 shares traded hands during trading, an increase of 269% from the average session volume of 75,046 shares. The stock had previously closed at $7.08.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on COYA. Chardan Capital reaffirmed a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Thursday, February 6th. HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, November 11th. Finally, D. Boral Capital reiterated a "buy" rating and set a $15.00 target price on shares of Coya Therapeutics in a research note on Thursday, February 6th.
Check Out Our Latest Report on Coya Therapeutics
Coya Therapeutics Stock Down 4.0 %
The stock has a market capitalization of $108.93 million, a price-to-earnings ratio of -10.03 and a beta of 0.47. The stock has a fifty day moving average of $6.17 and a 200-day moving average of $6.44.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. DME Capital Management LP boosted its stake in Coya Therapeutics by 29.2% in the fourth quarter. DME Capital Management LP now owns 1,646,440 shares of the company's stock valued at $9,434,000 after acquiring an additional 372,414 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Coya Therapeutics in the 4th quarter valued at about $74,000. Northern Trust Corp boosted its position in shares of Coya Therapeutics by 12.2% in the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company's stock valued at $164,000 after purchasing an additional 3,099 shares during the period. Tower Research Capital LLC TRC grew its stake in Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock worth $30,000 after buying an additional 4,777 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Coya Therapeutics during the fourth quarter worth approximately $59,000. 39.75% of the stock is owned by hedge funds and other institutional investors.
About Coya Therapeutics
(
Get Free Report)
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Featured Articles
Before you consider Coya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.
While Coya Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
